323 related articles for article (PubMed ID: 21788730)
1. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
Lewis RE; Liao G; Wang W; Prince RA; Kontoyiannis DP
Virulence; 2011; 2(4):348-55. PubMed ID: 21788730
[TBL] [Abstract][Full Text] [Related]
2. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
Lamaris GA; Ben-Ami R; Lewis RE; Chamilos G; Samonis G; Kontoyiannis DP
J Infect Dis; 2009 May; 199(9):1399-406. PubMed ID: 19358672
[TBL] [Abstract][Full Text] [Related]
3. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Bellanger AP; Albert ND; Lewis RE; Walsh TJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2015 Dec; 59(12):7830-2. PubMed ID: 26392499
[TBL] [Abstract][Full Text] [Related]
4. Preexposure to Isavuconazole Increases the Virulence of
Wurster S; Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455245
[TBL] [Abstract][Full Text] [Related]
5. Molecular Confirmation of the Linkage between the
Macedo D; Leonardelli F; Dudiuk C; Theill L; Cabeza MS; Gamarra S; Garcia-Effron G
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891608
[No Abstract] [Full Text] [Related]
6. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
[TBL] [Abstract][Full Text] [Related]
8. In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.
Krishnan Natesan S; Wu W; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):272-7. PubMed ID: 22897872
[TBL] [Abstract][Full Text] [Related]
9. In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.
Kachuei R; Khodavaisy S; Rezaie S; Sharifynia S
J Mycol Med; 2016 Mar; 26(1):17-21. PubMed ID: 26852191
[TBL] [Abstract][Full Text] [Related]
10. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
Lamaris GA; Ben-Ami R; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2008 Sep; 62(3):539-42. PubMed ID: 18544603
[TBL] [Abstract][Full Text] [Related]
11. Future directions in mucormycosis research.
Kontoyiannis DP; Lewis RE; Lortholary O; Spellberg B; Petrikkos G; Roilides E; Ibrahim A; Walsh TJ
Clin Infect Dis; 2012 Feb; 54 Suppl 1(Suppl 1):S79-85. PubMed ID: 22247450
[TBL] [Abstract][Full Text] [Related]
12. An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains.
Alcazar-Fuoli L; Buitrago M; Gomez-Lopez A; Mellado E
Virulence; 2015; 6(4):376-84. PubMed ID: 26065322
[TBL] [Abstract][Full Text] [Related]
13. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
14. The natural occurring Y129F polymorphism in Rhizopus oryzae (R. arrhizus) Cyp51Ap accounts for its intrinsic voriconazole resistance.
Macedo D; Leonardelli F; Cabeza MS; Gamarra S; Garcia-Effron G
Med Mycol; 2021 Dec; 59(12):1202-1209. PubMed ID: 34550395
[TBL] [Abstract][Full Text] [Related]
15. Comparison between Aspergillus fumigatus conidia and hyphae susceptibilities to amphotericin B, itraconazole, and voriconazole by use of the mold rapid susceptibility assay.
Wetter TJ; Hazen KC; Cutler JE
Med Mycol; 2005 Sep; 43(6):525-32. PubMed ID: 16323310
[TBL] [Abstract][Full Text] [Related]
16. How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
Lewis RE; Lortholary O; Spellberg B; Roilides E; Kontoyiannis DP; Walsh TJ
Clin Infect Dis; 2012 Feb; 54 Suppl 1():S67-72. PubMed ID: 22247448
[TBL] [Abstract][Full Text] [Related]
17. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
18. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.
Ben-Ami R; Lewis RE; Tarrand J; Leventakos K; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Jan; 54(1):484-90. PubMed ID: 19858263
[TBL] [Abstract][Full Text] [Related]
19. Reflections on the approach to treatment of a mycologic disaster.
Stevens DA
Antimicrob Agents Chemother; 2013 Apr; 57(4):1567-72. PubMed ID: 23384533
[No Abstract] [Full Text] [Related]
20. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
